1-20 of 38
Patrick Y. Wen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Manmeet S. Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E. Berens, Tobias Walbert, Matthias Holdhoff, Glenn J. Lesser, Timothy F. Cloughesy, Andrew E. Sloan, Naoko Takebe, Marta Couce, David M. Peereboom, Burt Nabors, Patrick Y. Wen, Stuart A. Grossman, Lisa R. Rogers
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3167–3178.
https://doi.org/10.1158/1078-0432.CCR-23-4098
Published: 01 August 2024
View article titled, Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Open the PDF for Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma

Mary Jane Lim-Fat, J. Bryan Iorgulescu, Rifaquat Rahman, Varun Bhave, Alona Muzikansky, Eleanor Woodward, Sydney Whorral, Marie Allen, Mehdi Touat, Xiaomei Li, Gongwen Xy, Jay Patel, Elizabeth R. Gerstner, Jayashree Kalpathy-Cramer, Gilbert Youssef, Ugonma Chukwueke, J. Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q. Lee, David A. Reardon, Rameen Beroukhim, Raymond Y. Huang, Wenya Linda Bi, Keith L. Ligon, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-23-3018
Published: 01 April 2024
View article titled, Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
Open the PDF for Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma

Benjamin M. Ellingson, Akifumi Hagiwara, Connor J. Morris, Nicholas S. Cho, Sonoko Oshima, Francesco Sanvito, Talia C. Oughourlian, Donatello Telesca, Catalina Raymond, Lauren E. Abrey, Josep Garcia, Dana T. Aftab, Colin Hessel, Tamar Rachmilewitz Minei, Dror Harats, David A. Nathanson, Patrick Y. Wen, Timothy F. Cloughesy
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4186–4195.
https://doi.org/10.1158/1078-0432.CCR-23-1235
Published: 13 October 2023
View article titled, Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
Open the PDF for Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients

K. Ina Ly, Leland G. Richardson, Mofei Liu, Alona Muzikansky, Jonathan Cardona, Kevin Lou, Andrew L. Beers, Ken Chang, James M. Brown, Xiaoyue Ma, David A. Reardon, Isabel C. Arrillaga-Romany, Deborah A. Forst, Justin T. Jordan, Eudocia Q. Lee, Jorg Dietrich, Lakshmi Nayak, Patrick Y. Wen, Ugonma Chukwueke, Anita Giobbie-Hurder, Bryan D. Choi, Tracy T. Batchelor, Jayashree Kalpathy-Cramer, William T. Curry, Elizabeth R. Gerstner
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3017–3025.
https://doi.org/10.1158/1078-0432.CCR-23-0203
Published: 15 August 2023
View article titled, Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
Open the PDF for Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma

Anne-Florence Blandin, Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K. Woods, Shakti Ramkissoon, Lori Ramkissoon, Frank Dubois, Kathleen Schoolcraft, Jessica Tsai, Dayle Wang, Robert Jones, Jayne Vogelzang, Kristine Pelton, Sarah Becker, Fiona Watkinson, Claire Sinai, Elizabeth F. Cohen, Matthew A. Booker, Michael Y. Tolstorukov, Veerle Haemels, Liliana Goumnerova, Karen Wright, Mark Kieran, Katie Fehnel, David Reardon, Arnault Tauziede-Espariat, Rishi Lulla, Benjamin Carcamo, Stanley Chaleff, Alain Charest, Frederik De Smet, Azra H. Ligon, Adrian Dubuc, Melanie Pages, Pascale Varlet, Patrick Y. Wen, Brian M. Alexander, Susan Chi, Sanda Alexandrescu, Ralf Kittler, Robert Bachoo, Pratiti Bandopadhayay, Rameen Beroukhim, Keith L. Ligon
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2651–2667.
https://doi.org/10.1158/1078-0432.CCR-21-3521
Published: 14 July 2023
View article titled, <em>ALK</em> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Open the PDF for <em>ALK</em> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials

Rifaquat Rahman, Steffen Ventz, Robert Redd, Timothy Cloughesy, Brian M. Alexander, Patrick Y. Wen, Lorenzo Trippa
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2194–2198.
https://doi.org/10.1158/1078-0432.CCR-22-3524
Published: 13 June 2023
View article titled, Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials
Open the PDF for Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials in another window
Journal Articles

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L. Clarke, Gavin P. Dunn, Michael Lim, Timothy Cloughesy, Hui K. Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew J. Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2567–2578.
https://doi.org/10.1158/1078-0432.CCR-21-4064
Published: 13 June 2022
View article titled, Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Open the PDF for Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

Laura Q.M. Chow, Fabrice Barlesi, Erin M. Bertino, Martin J. van den Bent, Heather A. Wakelee, Patrick Y. Wen, Chao-Hua Chiu, Sergey Orlov, Rita Chiari, Margarita Majem, Mark McKeage, Chong-Jen Yu, Pilar Garrido, Felipe K. Hurtado, Pilar Cazorla Arratia, Yuanbo Song, Fabrice Branle, Michael Shi, Dong-Wan Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2506–2516.
https://doi.org/10.1158/1078-0432.CCR-21-1838
Published: 13 June 2022
View article titled, ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <em>ALK</em>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Open the PDF for ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <em>ALK</em>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges in another window
Includes: Supplementary data
Journal Articles

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Andrew B. Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, Miguel J. Gil-Gil, Vinay K. Puduvalli, Jeffrey J. Raizer, Filip Y.F. De Vos, Patrick Y. Wen, Nicholas A. Butowski, Paul M.J. Clement, Morris D. Groves, Cristóbal Belda-Iniesta, Pierre Giglio, Harris S. Soifer, Steven Rowsey, Cindy Xu, Francesca Avogadri, Ge Wei, Susan Moran, Patrick Roth
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2270–2277.
https://doi.org/10.1158/1078-0432.CCR-21-2664
Published: 01 June 2022
View article titled, Infigratinib in Patients with Recurrent Gliomas and <em>FGFR</em> Alterations: A Multicenter Phase II Study
Open the PDF for Infigratinib in Patients with Recurrent Gliomas and <em>FGFR</em> Alterations: A Multicenter Phase II Study in another window
Includes: Supplementary data
Journal Articles

Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma

Kirit Singh, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, Susan M. Chang, Rifaquat Rahman, Evanthia Galanis, Alireza Mansouri, Vinay K. Puduvalli, David A. Reardon, Solmaz Sahebjam, John H. Sampson, John Simes, Donald A. Berry, Gelareh Zadeh, Tim F. Cloughesy, Minesh P. Mehta, Steven Piantadosi, Michael Weller, Amy B. Heimberger, Mustafa Khasraw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 585–593.
https://doi.org/10.1158/1078-0432.CCR-21-2681
Published: 15 February 2022
View article titled, Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Open the PDF for Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma in another window
Journal Articles

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Stephen J. Bagley, Shawn Kothari, Rifaquat Rahman, Eudocia Q. Lee, Gavin P. Dunn, Evanthia Galanis, Susan M. Chang, Louis Burt Nabors, Manmeet S. Ahluwalia, Roger Stupp, Minesh P. Mehta, David A. Reardon, Stuart A. Grossman, Erik P. Sulman, John H. Sampson, Simon Khagi, Michael Weller, Timothy F. Cloughesy, Patrick Y. Wen, Mustafa Khasraw
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 594–602.
https://doi.org/10.1158/1078-0432.CCR-21-2750
Published: 15 February 2022
View article titled, Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Open the PDF for Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement in another window
Journal Articles

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek M.E. Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, Leah Henegar, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael G. Kauffman, Sharon Shacham, Morten Mau-Sørensen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 452–460.
https://doi.org/10.1158/1078-0432.CCR-21-2225
Published: 01 February 2022
View article titled, A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Open the PDF for A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, III, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4491–4499.
https://doi.org/10.1158/1078-0432.CCR-21-0611
Published: 15 August 2021
View article titled, Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Open the PDF for Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, David A. Reardon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (4): 1048–1057.
https://doi.org/10.1158/1078-0432.CCR-20-2500
Published: 15 February 2021
View article titled, Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Open the PDF for Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma

Benjamin M. Ellingson, Jingwen Yao, Catalina Raymond, David A. Nathanson, Ararat Chakhoyan, Jeremy Simpson, James S. Garner, Alan G. Olivero, Lars U. Mueller, Jordi Rodon, Elizabeth Gerstner, Timothy F. Cloughesy, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3135–3144.
https://doi.org/10.1158/1078-0432.CCR-19-3817
Published: 01 July 2020
View article titled, Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma
Open the PDF for Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Patrick Y. Wen, Timothy F. Cloughesy, Alan G. Olivero, Kari M. Morrissey, Timothy R. Wilson, Xuyang Lu, Lars U. Mueller, Alexandre F. Coimbra, Benjamin M. Ellingson, Elizabeth Gerstner, Eudocia Q. Lee, Jordi Rodon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1820–1828.
https://doi.org/10.1158/1078-0432.CCR-19-2808
Published: 15 April 2020
View article titled, First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
Open the PDF for First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in another window
Journal Articles

A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma

Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert D. Aiken, Joseph C. Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael Glantz, David M. Peereboom, James M. Markert, Renato LaRocca, Donald M. O'Rourke, Karen Fink, Lyndon Kim, Michael Gruber, Glenn J. Lesser, Edward Pan, Santosh Kesari, Alona Muzikansky, Clemencia Pinilla, Radleigh G. Santos, John S. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5799–5807.
https://doi.org/10.1158/1078-0432.CCR-19-0261
Published: 01 October 2019
View article titled, A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Open the PDF for A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data

Steffen Ventz, Albert Lai, Timothy F. Cloughesy, Patrick Y. Wen, Lorenzo Trippa, Brian M. Alexander
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4993–5001.
https://doi.org/10.1158/1078-0432.CCR-19-0820
Published: 15 August 2019
View article titled, Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data
Open the PDF for Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data in another window
Includes: Supplementary data
Journal Articles

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

Varun V. Prabhu, Neel S. Madhukar, Coryandar Gilvary, C. Leah B. Kline, Sophie Oster, Wafik S. El-Deiry, Olivier Elemento, Faye Doherty, Alexander VanEngelenburg, Jessica Durrant, Rohinton S. Tarapore, Sean Deacon, Neil Charter, Jinkyu Jung, Deric M. Park, Mark R. Gilbert, Jessica Rusert, Robert Wechsler-Reya, Isabel Arrillaga-Romany, Tracy T. Batchelor, Patrick Y. Wen, Wolfgang Oster, Joshua E. Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2305–2313.
https://doi.org/10.1158/1078-0432.CCR-18-2572
Published: 01 April 2019
View article titled, Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Open the PDF for Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism in another window
Includes: Supplementary data
Journal Articles

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma

Eudocia Q. Lee, Dan G. Duda, Alona Muzikansky, Elizabeth R. Gerstner, John G. Kuhn, David A. Reardon, Lakshmi Nayak, Andrew D. Norden, Lisa Doherty, Debra LaFrankie, Jennifer Stefanik, Trupti Vardam, Katrina H. Smith, Christine McCluskey, Sarah Gaffey, Tracy T. Batchelor, Rakesh K. Jain, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4643–4649.
https://doi.org/10.1158/1078-0432.CCR-18-1025
Published: 01 October 2018
View article titled, Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma
Open the PDF for Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma in another window